Skip to main content
NIH funding notice RFA-DA-25-028

Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional)

Closed on July 9, 2024.

Posted
December 18, 2023
Close date
July 9, 2024
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

4 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $2,398,298 in first-year total cost, median $613,874.

Most frequent study sections

  1. Special Emphasis Panel[ZDA1 SAI-M (J2)]4

Most frequent institutions

  1. CITY COLLEGE OF NEW YORK1
  2. JOHNS HOPKINS UNIVERSITY1
  3. MCLEAN HOSPITAL1
  4. YALE UNIVERSITY1
Competing awards under RFA-DA-25-028 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2025Development and Validation of a Stimulant Use Disorder Severity Scale1UG3DA062919-01KILUK, BRIAN D.YALE UNIVERSITY, CT$818,486ZDA1
2025Developing an FDA-Qualified Clinical Outcomes Assessment for Opioid Withdrawal1UG3DA062907-01BRANDT, LAURADUNN, KELLY ECITY COLLEGE OF NEW YORK, NY$702,974ZDA1
2025Validating an Opioid Craving Assessment for FDA Qualification as a Drug Development Tool1UG3DA062905-01BERGERIA, CECILIAELLIS, JENNIFER DJOHNS HOPKINS UNIVERSITY, MD$524,774ZDA1
2025Development and Validation of a Measure of Substance-Related Consequences: A Novel Clinical Outcome Assessment for Substance Use Disorder Trials1UG3DA062906-01MCHUGH, REBECCA KATHRYNMCLEAN HOSPITAL, MA$352,064ZDA1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-10-0.1.1. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.

RFA-DA-25-028: Development of Clinical Outcome Assessments as New FDA-Qualified Drug Development Tools to Accelerate Therapeutics Development for Opioid and Stimulant Use Disorders (UG3/UH3 Clinical Trial Optional) | ScienceDex | ConductScience